tirzepatide pancreatitis gallbladder warning label A 54-year-old woman with obesity (BMI 38 kg/m²) and type 2 diabetes is being considered for semaglutide. Five years ago she developed acute secondary to gallstones. She underwent laparoscopic cholecystectomy and GLP-1 Pancreatitis Risk: MHRA Warning

Important Safety Information : Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Studies of long-term weight loss maintainers show 75% continue tracking daily or near-daily

Those are very valuable results, says Daniel Drucker, an endocrinologist at the University of Toronto

The standard Phase 2 trial schedule began at 0.5 to 1mg weekly, escalating every 4 weeks through 2mg, 4mg, 8mg, and up to 12mg

The SURMOUNT clinical trial program is one of the largest and most rigorous weight management study programs ever conducted

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)